OverviewSuggest Edit

Passage Bio is a genetic medicines company developing therapies for the treatment of rare monogenic central nervous system diseases. Passage Bio develops a portfolio of 5 rare disease indications in the neuro/CNS genetic space through IND-enabling studies using AAV technology and know-how.

TypePublic
Founded2018
HQPhiladelphia, PA, US
Websitepassagebio.com

Latest Updates

Employees (est.) (Dec 2019)20
Job Openings6
Share Price (Nov 2021)$8.8(+3%)
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Passage Bio

Bruce Goldsmith

Bruce Goldsmith

Chief Executive Officer
Karen Anderson

Karen Anderson

Vice President Medical Affairs
Andrea Campanile

Andrea Campanile

Vice President Clinical Operations
Steve Biroc

Steve Biroc

Vice President Project Management
Robin Derogatis

Robin Derogatis

Vice President Human Resources
Erin Brubaker

Erin Brubaker

Vice President Corporate Development
Show more

Passage Bio Office Locations

Passage Bio has an office in Philadelphia
Philadelphia, PA, US (HQ)
2001 Market St
Show all (1)

Passage Bio Financials and Metrics

Passage Bio Revenue

USD

Net income (Q1, 2021)

(38.9m)

EBIT (Q1, 2021)

(38.9m)

Market capitalization (12-Nov-2021)

462.6m

Closing stock price (12-Nov-2021)

8.8

Cash (31-Mar-2021)

249.5m
Passage Bio's current market capitalization is $462.6 m.
Annual
USDFY, 2018FY, 2019FY, 2020

General and administrative expense

928.0k7.0m30.1m

R&D expense

12.5m30.2m81.8m

Operating expense total

13.5m37.2m111.9m

EBIT

(13.5m)(37.2m)(112.9m)
Quarterly
USDQ1, 2020Q2, 2020Q1, 2021

General and administrative expense

4.8m7.4m12.5m

R&D expense

13.1m19.9m25.0m

Operating expense total

17.9m27.3m37.4m

EBIT

(17.9m)(27.3m)(38.9m)
Annual
USDFY, 2018FY, 2019FY, 2020

Cash

24.9m158.9m135.0m

Prepaid Expenses

8.5m6.9m1.4m

Current Assets

33.4m165.8m317.2m

PP&E

28.0k1.1m2.8m
Quarterly
USDQ1, 2020Q2, 2020Q1, 2021

Cash

366.8m353.4m249.5m

Prepaid Expenses

2.9m2.2m3.4m

Current Assets

382.1m368.2m450.9m

PP&E

1.1m1.1m6.6m
Annual
USDFY, 2018FY, 2019FY, 2020

Net Income

(12.8m)(45.6m)(112.2m)

Depreciation and Amortization

134.0k800.0k

Accounts Payable

(163.0k)2.0m4.6m

Cash From Operating Activities

(18.6m)(39.9m)(80.5m)
Quarterly
USDQ1, 2020Q2, 2020Q1, 2021

Net Income

(17.6m)(44.8m)(38.9m)

Depreciation and Amortization

49.0k247.0k211.0k

Accounts Payable

331.0k6.5m592.0k

Cash From Operating Activities

(21.9m)(33.6m)(30.7m)
USDFY, 2018

Financial Leverage

-2.7 x
Show all financial metrics

Passage Bio Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Passage Bio Online and Social Media Presence

Embed Graph

Passage Bio News and Updates

Passage Bio Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

PHILADELPHIA, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced it has granted an inducement award to a new employee.

Passage Bio to Present at Guggenheim 3rd Annual Neuro/Immunology Conference

PHILADELPHIA, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, today announced that Bruce Goldsmith, Ph.D., president and chief executive officer of Pa…

Passage Bio Reports Third Quarter 2021 Financial Results and Provides Recent Business Highlights

PHILADELPHIA, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, today reported financial results for the third quarter ended September 30, 2021 and prov…

Passage Bio to Participate in Upcoming October Conferences

PHILADELPHIA, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that management will participate in two upcoming conferences in October:

Passage Bio Announces Maxine Gowen, Ph.D., as Chairwoman of the Board of Directors

PHILADELPHIA, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today reported that Maxine Gowen, Ph.D., has been appointed chairwoman of the boa…

Passage Bio to Present at Citi 16th Annual BioPharma Virtual Conference

PHILADELPHIA, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, today announced that Bruce Goldsmith, Ph.D., president and chief executive officer of P…
Show more

Passage Bio Frequently Asked Questions

  • When was Passage Bio founded?

    Passage Bio was founded in 2018.

  • Who are Passage Bio key executives?

    Passage Bio's key executives are Bruce Goldsmith, Karen Anderson and Andrea Campanile.

  • How many employees does Passage Bio have?

    Passage Bio has 20 employees.

  • Who are Passage Bio competitors?

    Competitors of Passage Bio include Taysha Gene Therapies, Angionetics and DegenRx.

  • Where is Passage Bio headquarters?

    Passage Bio headquarters is located at 2001 Market St, Philadelphia.

  • Where are Passage Bio offices?

    Passage Bio has an office in Philadelphia.

  • How many offices does Passage Bio have?

    Passage Bio has 1 office.